New schizophrenia drug candidate TAK-063 begins safety testing
NCT ID NCT01879722
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested the safety and tolerability of multiple doses of TAK-063 in 77 participants, including people with stable schizophrenia and healthy Japanese volunteers. Researchers monitored side effects, lab results, and vital signs over 7 days. The study does not aim to treat schizophrenia but to gather initial safety data for future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TAK-063
What this could lead to
If successful, this could pave the way for larger studies to see if TAK-063 helps control schizophrenia symptoms.
What could go wrong
This is a very early Phase 1 trial focused only on safety, not on whether the drug works. The drug may cause side effects or fail in later stages.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Glendale, California, United States